April 15, 2020

Case WA# 214942

VIA Electronic Mail

Kristopher Fishman, President and CEO
Wells Pharmacy Network, Inc.
3420 Fairlane Farms Road, Suite 300
Wellington, Florida 33414
kfishman@wellsrx.com

Mr. Fishman,

In a separate electronic mail, we will be enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Wells Pharmacy Network, LLC, located at 450 US Highway 51 BYP North, Dyersburg, Tennessee 38024-3655, from April 16, 2018, to April 27, 2018, by the U.S. Food and Drug Administration (FDA).

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Rebecca Asente, Compliance Officer, via (504) 846-8104 or rebecca.asente@fda.hhs.gov.

Sincerely,

John W.
Diehl -S3
John W. Diehl, M.S
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov